DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors. Source
No articles found.
Harvard Bioscience is a global developer, manufacturer and marketer of a broad ran...
Harvard Bioscience is a global developer, manuf...
Allied Healthcare Products, Inc. is a leading manufacturer of medical gas construc...
Allied Healthcare Products, Inc. is a leading m...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Aduro is dedicated to its mission to discover, develop, and commercialize immunoth...
Aduro is dedicated to its mission to discover, ...
Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering n...
Revance Therapeutics is a Silicon Valley-based ...
Nymox Pharmaceutical Corporation specializes in the research and development of th...
Nymox Pharmaceutical Corporation specializes in...
Celcuity is a cellular analysis company that is discovering new cancer sub-types a...
Celcuity is a cellular analysis company that is...
Join the National Investor Network and get the latest information with your interests in mind.